Literature DB >> 1549239

Lack of association between anticardiolipin antibodies and migraine in systemic lupus erythematosus.

J Montalbán1, R Cervera, J Font, J Ordi, J Vianna, H J Haga, M Tintoré, M A Khamashta, G R Hughes.   

Abstract

We carried out a prospective study of the prevalence and characteristics of anticardiolipin antibodies (aCL) and migraine on 103 consecutive patients with systemic lupus erythematosus (SLE) derived from three European referral university centers. We also included a control group of 58 patients with migraine not associated with SLE. We interviewed all patients using a data collection form designed to provide a complete record of the clinical characteristics of headache. Fifty-four (52%) patients with SLE suffered recurrent headache. We diagnosed migraine in 32 patients, tension headache in 21, and cluster headache in one. Thirty (29%) patients with SLE had aCL. Migraine was present in five patients with aCL and in 27 patients without aCL (17% versus 37%, p = 0.07). No migraine control patient had aCL. Our study highlights the frequency of headache in SLE, but does not support an association between the presence of aCL and migraine in this disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1549239     DOI: 10.1212/wnl.42.3.681

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  Prevalence and classification of headache in patients with systemic lupus erythematosus.

Authors:  Bruno Lessa; Alex Santana; Isabella Lima; José Martônio Almeida; Mittermayer Santiago
Journal:  Clin Rheumatol       Date:  2006-01-26       Impact factor: 2.980

2.  [Neurological manifestations in connective tissue disease].

Authors:  L Harms; F Hiepe
Journal:  Z Rheumatol       Date:  2012-09       Impact factor: 1.372

3.  Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model.

Authors:  L Ziporen; Y Shoenfeld; Y Levy; A D Korczyn
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

4.  [Primary headaches and the influence of inflammatory diseases of the CNS and their respective immunmodulatory therapy].

Authors:  M Empl; A Straube
Journal:  Schmerz       Date:  2007-10       Impact factor: 1.107

Review 5.  Antiphospholipid syndrome and vascular ischemic (occlusive) diseases: an overview.

Authors:  Penka A Atanassova
Journal:  Yonsei Med J       Date:  2007-12-31       Impact factor: 2.759

Review 6.  Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria?

Authors:  Mohammad Hassan A Noureldine; Ali A Haydar; Ahmad Berjawi; Rody Elnawar; Ahmad Sweid; Munther A Khamashta; Graham R V Hughes; Imad Uthman
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

Review 7.  Neurologic manifestations of the antiphospholipid syndrome.

Authors:  Jose F Roldan; Robin L Brey
Journal:  Curr Rheumatol Rep       Date:  2007-05       Impact factor: 4.592

8.  Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus.

Authors:  Tomasz Hawro; Andrzej Bogucki; Maria Krupińska-Kun; Marcus Maurer; Anna Woźniacka
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

9.  Determination of the Risk Factors Contributing to the Development of Neuropsychiatric Lupus in a Systemic Lupus Erythematosus Cohort.

Authors:  Adegbenga A Bankole; Taskeen R Kazmi; Alyssa R Strazanac
Journal:  Cureus       Date:  2021-12-03

Review 10.  Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms.

Authors:  Leonardo Biscetti; Gioacchino De Vanna; Elena Cresta; Ilenia Corbelli; Lorenzo Gaetani; Letizia Cupini; Paolo Calabresi; Paola Sarchielli
Journal:  J Neuroinflammation       Date:  2021-11-08       Impact factor: 8.322

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.